Ketty Peris

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 584 publications

Corrigendum to "Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology" [Digestive and Liver Disease 58 (2026) 1051-1060].

Corrigendum to "Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology" [Digestive and Liver Disease 58 (2026) 1051-1060].

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: August 30, 2026

Sequencing and switching among IL-17 and IL-23 biologics in plaque psoriasis: real-world lessons and precision strategies for the future.

Sequencing and switching among IL-17 and IL-23 biologics in plaque psoriasis: real-world lessons and precision strategies for the future.

Journal: Expert opinion on biological therapy
Published: July 23, 2026

Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.

Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.

Journal: International journal of dermatology
Published: July 02, 2026

Line-Field Confocal Optical Coherence Tomography (LC-OCT) of Spitz Naevi: Preliminary Observations According to Dermoscopic Patterns.

Line-Field Confocal Optical Coherence Tomography (LC-OCT) of Spitz Naevi: Preliminary Observations According to Dermoscopic Patterns.

Journal: International journal of dermatology
Published: June 25, 2026

LC-OCT for Cutaneous Lupus Erythematosus: Characterization Across Disease Subtypes and Differentiation From Rosacea.

LC-OCT for Cutaneous Lupus Erythematosus: Characterization Across Disease Subtypes and Differentiation From Rosacea.

Journal: Experimental dermatology
Published: June 17, 2026

Toward context-aware and not context-driven, AI in dermoscopic diagnosis. Response to "The cost of AI sycophancy in dermoscopic diagnosis."

Toward context-aware and not context-driven, AI in dermoscopic diagnosis. Response to "The cost of AI sycophancy in dermoscopic diagnosis."

Journal: Journal of the American Academy of Dermatology
Published: May 27, 2026

The Cape Town Action Plan for Neglected Tropical Skin Diseases: From Workshop Consensus to Health-System Action.

The Cape Town Action Plan for Neglected Tropical Skin Diseases: From Workshop Consensus to Health-System Action.

Journal: International journal of dermatology
Published: May 27, 2026

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

Journal: Research square
Published: May 25, 2026

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

Journal: Research square
Published: May 25, 2026

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Journal: The British journal of dermatology
Published: May 16, 2026

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Journal: Clinical and experimental dermatology
Published: April 12, 2026

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2026
Showing 1-12 of 584

Last Updated: 09/26/2026